Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GOVX GeoVax Labs	$0.85 +3.3%	$0.91	$0.43 ▼ $11.18	$13.49M	3.36	988,829 shs	440,125 shs
LTRN Lantern Pharma	$4.27 +6.0%	$3.39	$2.55 ▼ $6.12	$46.38M	1.54	98,486 shs	3.48 million shs
MDCX Medicus Pharma	$3.08	$3.83	$1.80 ▼ $8.94	$41.81M	N/A	198,195 shs	114,713 shs
MRSN Mersana Therapeutics	$0.40 +9.7%	$0.35	$0.26 ▼ $2.83	$49.85M	0.79	2.77 million shs	1.65 million shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GOVX GeoVax Labs	0.00%	+18.82%	-13.14%	-3.30%	-69.29%
LTRN Lantern Pharma	+6.33%	+7.18%	+26.73%	+8.04%	-12.77%
MDCX Medicus Pharma	+0.65%	+3.70%	+23.69%	-21.43%	+307,999,900.00%
MRSN Mersana Therapeutics	+1.22%	+11.53%	-0.60%	-6.74%	-81.82%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GOVX GeoVax Labs	2.1595 of 5 stars	3.6	2.0	0.0	2.8	0.0	0.6
LTRN Lantern Pharma	2.8282 of 5 stars	3.5	5.0	0.0	1.5	0.8	0.6
MDCX Medicus Pharma	2.4088 of 5 stars	3.8	0.0	0.0	3.0	1.7	0.0
MRSN Mersana Therapeutics	3.8364 of 5 stars	3.5	3.0	4.1	0.6	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GOVX GeoVax Labs	3.00	Buy	$8.88	947.69% Upside
LTRN Lantern Pharma	3.00	Buy	$25.00	485.48% Upside
MDCX Medicus Pharma	3.50	Strong Buy	$23.50	662.99% Upside
MRSN Mersana Therapeutics	3.00	Buy	$5.20	1,203.26% Upside

Current Analyst Ratings Breakdown

Latest GOVX, LTRN, MRSN, and MDCX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/17/2025	GOVX GeoVax Labs	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
7/9/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
7/1/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
6/23/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
6/16/2025	GOVX GeoVax Labs	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
6/9/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
6/3/2025	MRSN Mersana Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
5/29/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
5/22/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00 ➝ $27.00
5/16/2025	MRSN Mersana Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $10.00
5/16/2025	MRSN Mersana Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00

(Data available from 7/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GOVX GeoVax Labs	$5.59M	2.41	N/A	N/A	$0.48 per share	1.76
LTRN Lantern Pharma	N/A	N/A	N/A	N/A	$1.96 per share	N/A
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	$0.29 per share	N/A
MRSN Mersana Therapeutics	$40.50M	1.23	N/A	N/A	($0.08) per share	-4.99

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GOVX GeoVax Labs	-$24.99M	-$3.65	N/A	N/A	N/A	-438.20%	-511.96%	-286.58%	8/5/2025 (Estimated)
LTRN Lantern Pharma	-$20.78M	-$1.84	N/A	N/A	N/A	N/A	-83.26%	-70.65%	8/6/2025 (Estimated)
MDCX Medicus Pharma	-$11.16M	-$1.16	N/A	N/A	N/A	N/A	-380.03%	-224.22%	7/24/2025 (Estimated)
MRSN Mersana Therapeutics	-$69.19M	-$0.59	N/A	N/A	N/A	-217.63%	-990.16%	-48.87%	8/12/2025 (Estimated)

Latest GOVX, LTRN, MRSN, and MDCX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	LTRN Lantern Pharma	-$0.53	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	MRSN Mersana Therapeutics	-$0.18	N/A	N/A	N/A	$6.06 million	N/A
8/5/2025	Q2 2025	GOVX GeoVax Labs	-$0.41	N/A	N/A	N/A	$0.37 million	N/A
7/24/2025	N/A	MDCX Medicus Pharma	-$0.39	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q1 2025	LTRN Lantern Pharma	-$0.49	-$0.42	+$0.07	-$0.42	N/A	N/A
5/15/2025	Q1 2025	MRSN Mersana Therapeutics	-$0.21	-$0.19	+$0.02	-$0.19	$6.05 million	$2.75 million
5/12/2025	Q1 2025	MDCX Medicus Pharma	-$0.23	-$0.42	-$0.19	-$0.42	N/A	N/A
5/1/2025	Q1 2025	GOVX GeoVax Labs	-$0.59	-$0.45	+$0.14	-$0.45	$0.75 million	$1.64 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GOVX GeoVax Labs	N/A	N/A	N/A	N/A	N/A
LTRN Lantern Pharma	N/A	N/A	N/A	N/A	N/A
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	N/A
MRSN Mersana Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GOVX GeoVax Labs	N/A	3.62	3.62
LTRN Lantern Pharma	N/A	4.86	4.86
MDCX Medicus Pharma	N/A	1.53	1.53
MRSN Mersana Therapeutics	N/A	1.83	1.83

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GOVX GeoVax Labs	6.09%
LTRN Lantern Pharma	28.62%
MDCX Medicus Pharma	N/A
MRSN Mersana Therapeutics	93.92%

Insider Ownership

Company	Insider Ownership
GOVX GeoVax Labs	5.70%
LTRN Lantern Pharma	7.31%
MDCX Medicus Pharma	11.20%
MRSN Mersana Therapeutics	13.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GOVX GeoVax Labs	10	15.93 million	15.02 million	Not Optionable
LTRN Lantern Pharma	20	10.79 million	10.00 million	Optionable
MDCX Medicus Pharma	N/A	13.57 million	12.05 million	N/A
MRSN Mersana Therapeutics	150	124.63 million	108.43 million	Optionable

GOVX, LTRN, MRSN, and MDCX Headlines

Recent News About These Companies

Mersana Therapeutics Settles Debt with Oxford Finance

July 3, 2025 | tipranks.com

Mersana Therapeutics Inc (MRSN) - Investing.com

July 2, 2025 | investing.com

Mersana Therapeutics Reports Additional Positive Interim Phase 1 Clinical Data for Emi-Le in Oral Presentation at 2025 ASCO Annual Meeting

June 2, 2025 | globenewswire.com

Mersana Therapeutics to Present at Upcoming Investor Conferences

May 20, 2025 | globenewswire.com

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q1 2025 Earnings Call Transcript

May 16, 2025 | insidermonkey.com

Q1 2025 Mersana Therapeutics Inc Earnings Call

May 16, 2025 | uk.finance.yahoo.com

Mersana Therapeutics Inc (MRSN) Q1 2025 Earnings Call Highlights: Strategic Restructuring and ...

May 16, 2025 | finance.yahoo.com

Mersana extends cash runway into mid-2026 as restructuring narrows focus to breast cancer

May 15, 2025 | msn.com

CORRECTION - Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results

May 15, 2025 | finance.yahoo.com

CORRECTION - Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results

May 15, 2025 | globenewswire.com

Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Lags Revenue Estimates

May 15, 2025 | zacks.com

Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results

May 15, 2025 | finance.yahoo.com

Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results

May 15, 2025 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: Mersana Therapeutics (MRSN) and IQVIA Holdings (IQV)

May 9, 2025 | theglobeandmail.com

Mersana Therapeutics announces strategic cutbacks amid economic pressures

May 7, 2025 | investing.com

Mersana makes Emi-Le the one, laying off 55% of staff to narrow focus to B7-H4 ADC

May 6, 2025 | fiercebiotech.comF

Mersana Therapeutics Announces Strategic Restructuring and Reprioritization Plan Focused on Advancing Emi-Le in Triple-Negative Breast Cancer

May 6, 2025 | globenewswire.com

Why Mersana Therapeutics, Inc.’s (MRSN) Stock Is Down 8.13%

May 2, 2025 | aaii.comA

Mersana Therapeutics Announces Upcoming Emi-Le Oral and Poster Presentations at ASCO 2025 Annual Meeting

April 23, 2025 | globenewswire.com

Mersana Therapeutics Announces Upcoming Oral Presentation of Emi-Le Clinical Data at European Society for Medical Oncology (ESMO) Breast Cancer 2025 Annual Congress

April 1, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GOVX, LTRN, MRSN, and MDCX Company Descriptions

GeoVax Labs NASDAQ:GOVX

$0.85 +0.03 (+3.30%)

As of 11:17 AM Eastern

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.

Lantern Pharma NASDAQ:LTRN

$4.27 +0.24 (+5.96%)

As of 11:36 AM Eastern

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

Medicus Pharma NASDAQ:MDCX

$3.08 0.00 (0.00%)

As of 11:18 AM Eastern

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.

Mersana Therapeutics NASDAQ:MRSN

$0.40 +0.04 (+9.71%)

As of 11:36 AM Eastern

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time